ATE415396T1 - Pyrazine derivate als tyrosin kinase modulatoren - Google Patents

Pyrazine derivate als tyrosin kinase modulatoren

Info

Publication number
ATE415396T1
ATE415396T1 AT01975243T AT01975243T ATE415396T1 AT E415396 T1 ATE415396 T1 AT E415396T1 AT 01975243 T AT01975243 T AT 01975243T AT 01975243 T AT01975243 T AT 01975243T AT E415396 T1 ATE415396 T1 AT E415396T1
Authority
AT
Austria
Prior art keywords
tyrosine kinase
pyrazine derivatives
kinase modulators
modulators
pyrazine
Prior art date
Application number
AT01975243T
Other languages
English (en)
Inventor
Gee Kuo
Peter Connolly
Catherine Prouty
Alan Deangelis
Aihua Wang
Linda Jolliffe
Steve Middleton
Stuart Emanuel
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22879359&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE415396(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE415396T1 publication Critical patent/ATE415396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT01975243T 2000-09-20 2001-09-19 Pyrazine derivate als tyrosin kinase modulatoren ATE415396T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23396800P 2000-09-20 2000-09-20

Publications (1)

Publication Number Publication Date
ATE415396T1 true ATE415396T1 (de) 2008-12-15

Family

ID=22879359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01975243T ATE415396T1 (de) 2000-09-20 2001-09-19 Pyrazine derivate als tyrosin kinase modulatoren

Country Status (14)

Country Link
US (1) US6710048B2 (de)
EP (1) EP1330452B1 (de)
JP (1) JP2004523474A (de)
AR (1) AR035494A1 (de)
AT (1) ATE415396T1 (de)
AU (1) AU9458401A (de)
CA (1) CA2423050A1 (de)
DE (1) DE60136731D1 (de)
DK (1) DK1330452T3 (de)
ES (1) ES2315308T3 (de)
HK (1) HK1054393B (de)
PT (1) PT1330452E (de)
TW (1) TWI254711B (de)
WO (1) WO2002024681A2 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040077605A1 (en) * 2001-06-20 2004-04-22 Salvati Mark E. Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
EP1854798A3 (de) * 2000-09-19 2007-11-28 Bristol-Myers Squibb Company Kondensierte heterozyklische Succinimid-Verbindungen und Analoga daraus, Modulatoren der nuklearen Hormonrezeptorfunktion
US20040087548A1 (en) 2001-02-27 2004-05-06 Salvati Mark E. Fused cyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
AU2002364082A1 (en) * 2001-12-19 2003-07-09 Bristol-Myers Squibb Company Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
US7482366B2 (en) * 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
CA2484209C (en) * 2002-05-03 2013-06-11 Exelixis, Inc. Protein kinase modulators and methods of use
AUPS251402A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Kinase inhibitors
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
US7015227B2 (en) * 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
GB0215775D0 (en) * 2002-07-06 2002-08-14 Astex Technology Ltd Pharmaceutical compounds
JP4483581B2 (ja) * 2002-08-06 2010-06-16 東レ株式会社 腎疾患治療又は予防剤及び腎疾患の診断方法
JP4896518B2 (ja) * 2002-12-13 2012-03-14 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド ニコチンアミド系キナーゼ阻害薬
US20040121968A1 (en) * 2002-12-23 2004-06-24 Alexander Ljubimov Antiangiogenesis by inhibiting protein kinase CK2 activity
RS53118B (sr) * 2003-02-26 2014-06-30 Sugen Inc. Aminoheteroaril jedinjenja kao inhibitori protein kinaze
GB2400101A (en) * 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
EP1644365A2 (de) * 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazin- und pyridinderivative als rho-kinase-inhibitoren
MXPA06003615A (es) * 2003-09-30 2006-06-05 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
BRPI0416853A (pt) * 2003-11-24 2007-02-13 Hoffmann La Roche pirazolila e imidazolila pirimidinas
EP1694670A1 (de) * 2003-12-16 2006-08-30 GPC Biotech AG Pyrazinderivate als gegen infektionskrankheiten wirksame verbindungen
WO2005072826A2 (en) 2004-01-21 2005-08-11 Emory University Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
CA2585490A1 (en) * 2004-11-12 2006-05-18 Galapagos Nv Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
GB0428082D0 (en) * 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
GB0500226D0 (en) * 2005-01-07 2005-02-16 Biofocus Discovery Ltd Compounds which bind to the active site of protein kinase enzymes
KR100674813B1 (ko) * 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
US8466154B2 (en) 2006-10-27 2013-06-18 The Board Of Regents Of The University Of Texas System Methods and compositions related to wrapping of dehydrons
RU2459819C2 (ru) * 2007-05-16 2012-08-27 Байер Кропсайенс Аг Фунгицидные фенилпиримидиниламино производные
WO2009037247A1 (en) * 2007-09-17 2009-03-26 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
KR100898037B1 (ko) * 2007-10-05 2009-06-01 한국화학연구원 금속촉매의 커플링반응에 의한 트리알킬피라진 유도체의제조방법
EP2288607B1 (de) 2008-06-09 2014-09-24 Sanofi Sulfonamide mit heterozyklen und einer oxadiazolon-kopfgruppe, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutika
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
NZ598262A (en) * 2009-08-17 2014-05-30 Sloan Kettering Inst Cancer Heat shock protein binding compounds, compositions, and methods for making and using same
MX2012002758A (es) * 2009-09-04 2012-04-19 Novartis Ag Pirazinil-piridinas utiles para el tratamiento de enfermedades proliferativas.
US20110185353A1 (en) * 2010-01-27 2011-07-28 Jack Matthew Mitigating Problems Arising From Incompatible Software
CN103298787A (zh) * 2010-11-17 2013-09-11 诺瓦提斯公司 3-(氨基芳基)-吡啶化合物
JP2014506878A (ja) * 2011-01-28 2014-03-20 ノバルティス アーゲー Ｃｄｋ９阻害剤としての置換ビ−ヘテロアリール化合物およびそれらの使用
ES2698847T3 (es) * 2011-07-07 2019-02-06 Merck Patent Gmbh Azaheterociclos sustituidos para el tratamiento del cáncer
JP6412503B2 (ja) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド 置換逆ピリミジンＢｍｉ−１阻害剤
KR102232595B1 (ko) 2013-08-30 2021-03-26 피티씨 테라퓨틱스, 인크. 치환된 피리미딘 bmi-1 저해제
EP3071553A4 (de) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituierte pyridin- und pyrazin-bmi-1-hemmer
EA201692155A1 (ru) 2014-05-13 2017-04-28 Мемориал Слоун-Кеттеринг Кэнсэ Сентр МОДУЛЯТОРЫ Hsp70 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
JP7249950B2 (ja) 2017-03-27 2023-03-31 カーデュリオン・ファーマシューティカルズ・リミテッド・ライアビリティ・カンパニー ヘテロ環化合物
GB201715318D0 (en) 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
GB201715414D0 (en) * 2017-09-22 2017-11-08 Syngenta Participations Ag Improvements in or relating to organic compounds
JP2021535198A (ja) 2018-08-17 2021-12-16 ピーティーシー セラピューティクス， インコーポレイテッド 膵臓癌を治療する方法
EP3856188B1 (de) 2018-09-25 2023-06-21 Cardurion Pharmaceuticals, Inc. Aminopyrimidin-verbindung
BR112023000588A8 (pt) 2020-07-15 2023-05-09 Chiesi Farm Spa Derivados de piridazinil amino como inibidores de alk5
PE20240148A1 (es) 2020-09-28 2024-02-06 Cardurion Pharmaceuticals Inc COMPUESTOS DE HETEROARILO FUSIONADO Y SU USO COMO INHIBIDORES DE CaMKII
AU2022351219A1 (en) 2021-09-21 2024-05-02 Chiesi Farmaceutici S.P.A. Pyridazinyl amino derivatives as alk5 inhibitors
MX2024008558A (es) 2022-01-11 2024-07-22 Chiesi Farm Spa Derivados de piridazinil amino como inhibidores del receptor del factor de crecimiento transformante b de tipo i (alk5).

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4514400A (en) * 1981-10-26 1985-04-30 William H. Rorer, Inc. Cardiotonic 5-heteroaryl-pyridone
DE4426346A1 (de) * 1994-07-25 1996-02-01 Basf Ag Herbizide Pyrazinderivate
GB9514160D0 (en) * 1994-07-25 1995-09-13 Zeneca Ltd Aromatic compounds
CA2294990C (en) 1997-06-30 2007-03-06 William Scott Caldwell Pharmaceutical compositions and methods for effecting dopamine release
DE69912279T2 (de) * 1998-06-30 2004-07-29 Eli Lilly And Co., Indianapolis 5-ht1f agonisten
ES2283315T3 (es) * 1999-09-16 2007-11-01 Tanabe Seiyaku Co., Ltd. Compuestos ciclicos de 6 miembros que contienen nitrogeno aromatico.
CN1231473C (zh) * 2000-02-16 2005-12-14 神经能质公司 取代的芳基吡嗪

Also Published As

Publication number Publication date
ES2315308T3 (es) 2009-04-01
HK1054393A1 (en) 2003-11-28
DE60136731D1 (de) 2009-01-08
DK1330452T3 (da) 2009-03-16
JP2004523474A (ja) 2004-08-05
HK1054393B (en) 2009-08-28
WO2002024681A2 (en) 2002-03-28
WO2002024681A3 (en) 2002-06-20
US20030060629A1 (en) 2003-03-27
PT1330452E (pt) 2009-01-22
CA2423050A1 (en) 2002-03-28
AU9458401A (en) 2002-04-02
TWI254711B (en) 2006-05-11
EP1330452A2 (de) 2003-07-30
AR035494A1 (es) 2004-06-02
US6710048B2 (en) 2004-03-23
EP1330452B1 (de) 2008-11-26

Similar Documents

Publication Publication Date Title
DE60136731D1 (de) Pyrazine derivate als tyrosin kinase modulatoren
ATE309996T1 (de) Chinolinonderivate als tyrosin-kinase inhibitoren
ATE316527T1 (de) Substituierte indolinone als tyrosinkinase inhibitoren
ATE286045T1 (de) Tyrosin kinaseinhibitoren
ATE255575T1 (de) Substituierte 3-cyanochinoline als protein tyrosine kinase inhibitoren
ATE445613T1 (de) Indolylmaleimidderivative als proteinkinase-c- inhibitoren
EP1161433A4 (de) Tyrosin-kinase-inhibitoren
DE60110616D1 (de) Pyrazolverbindungen als protein-kinasehemmer
DE60119777D1 (de) Pyrazolverbindungen als protein-kinasehemmer
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE395346T1 (de) Chinazolinderivate als tyrosinkinaseinhibitoren
CY2014034I1 (el) Υποκατεστημενες 3-κυανοκινολινες ως αναστολεις κινασων πρωτεϊνης τυροσινης
NO20014970L (no) Cyklisk protein-tyrosin-kinase-inhibitor
IS6968A (is) Nýir týrósínkínasa tálmar
DE69511253D1 (de) Wasserlösliche 3-arylidene-2-oxindole derivate als tyrosine kinase inhibitoren
NO20024235D0 (no) 5-alkylpyrido(2,3-D)pyrimidin tyrosin kinase inhibitorer
DE60113533D1 (de) Derivate von beta-aminosäurenitrilen
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DK1226136T3 (da) Tyrosinkinaseinhibitor

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1330452

Country of ref document: EP

RZN Patent revoked